the Effect of Integrated Neuomuscular Inhibition Technique on Adult Females With Cervicogenic Headache

Status: Recruiting
Location: See location...
Intervention Type: Drug, Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Methods: Forty females with cervicogenic headache will be recruited. Patients will be randomly assigned into two groups, group A and group B . Patients in both groups will receive a traditional medical treatment, but group (B) will receive additional integrated neuromuscular inhibition technique.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 60
Healthy Volunteers: f
View:

• 1 - A diagnosis of CGH will be made by an experienced neurologist as per the International Classification of Headache Disorders 3rd edition (ICHD-3) , but not including occipital nerve blockage 2-Additional inclusion criteria will include female patients aged\> 18 years and\<60 years.

• 3-headache intensity ≥ 3 on eleven-point numerical rating scale at enrolment. 4-at least three-month history of headache with a mean frequency of \> 1/week. 5-hypomobility of the upper cervical spine (C0 to C3) on manual examination; and reproduction of the headache on palpation of the upper cervical spine (C0 to C3).

• 6-In addition, patients should exhibit active trigger points within the suboccipital, and upper trapezius muscles, ipsilaterally over the symptomatic side reproducing their headache symptoms .

Locations
Other Locations
Egypt
Khalid enb elwaleed polyclinic
RECRUITING
Tanta
Contact Information
Primary
Jilan Adel, lecturer
gelan_youssif@pt.kfs.edu.eg
01007519909
Time Frame
Start Date: 2025-06-16
Estimated Completion Date: 2025-10-14
Participants
Target number of participants: 40
Treatments
Other: Control group
All patients will receive a traditional medical program by an experienced neurologist in the form of Muscle relaxants tizanidine ,4 mg to 32 mg, Three times a day.
Experimental: experimental group
Patients in experimental group (B) will receive the same program as control group (A) plus the INIT for upper trapezius and suboccipital muscles. The INIT program will be administrated three times a week for one month.
Related Therapeutic Areas
Sponsors
Leads: Kafrelsheikh University

This content was sourced from clinicaltrials.gov